Truscreen Group Limited announced the resignation of Dr. Beata Edling due to personal reasons effective immediately and will assist in the transition to an interim CEO in the coming weeks. Beata has personal commitments to family in Poland and will be available to assist TruScreen on a consulting basis to further the business in Poland and central Europe. Beata first joined TruScreen in 2020 as Head of Medical Affairs and after the COVID pandemic was appointed CEO in October 2022.

Under her leadership, TruScreen's commercialisation has demonstrated solid growth, culminating in TruScreen's technology being put on the National Guidelines of China's CSCCP and COGA's Blue Book, plus Vietnam's MOH National Technical List and the recent Mexico's Cofeperis approval for the Public health sector. Her contribution has set the foundation for the company's further growth. Mr. Martin Dillon, who was CEO from 2013 to 2019, will be appointed Interim CEO.

TruScreen's key China business will report directly to the Chairman. Martin previously successfully established the global distribution network, launched the TruScreen Ultra2 device, knows the technology and is well known to distributors. Martin also managed the listing of TruScreen on the NZX in 2014.